Overview
BMY market data
Price History
BMY price chart · 1M
- O
- 67.47
- H
- 67.70
- L
- 66.58
- C
- 66.83
- Vol
- 247,843.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $67.47
- Previous Close
- $68.07
- Day High
- $67.70
- Day Low
- $66.58
- 52 Week High
- $68.64
- 52 Week Low
- $52.84
- 7 Day Return
- +0.37%
- 30 Day Return
- +5.02%
- 90 Day Return
- +21.59%
- 1 Year Return
- +21.41%
- Daily Notional Volume
- $16.6M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 14.70 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.6% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 18.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.52 – $68.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $136.5B · P/B 5.94 · P/S 2.78.
Company News
10 captured
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Zacks Investment Research ·
Cancer Survivors to Swim 28.5 Miles Around Manhattan to Fund Cancer Care in KenyaGlobenewswire Inc ·
Is BioNTech Stock a No-Brainer Buy on the Dip?The Motley Fool ·
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?Zacks Investment Research ·
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B DealZacks Investment Research ·